RCHAinactive

RICH PHARMACEUTICALS, INC.

Healthcare·Neurology·Pre-clinical
Neurology

RICH PHARMACEUTICALS, INC. (RCHA): 1 pipeline candidate. Updated within the last hour.

5.1/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.01

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for RICH PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$6K

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (1 candidate)

DrugPhase
rp-323Preclinical

Frequently asked questions

How many drug candidates are in RICH PHARMACEUTICALS, INC.'s pipeline?

RICH PHARMACEUTICALS, INC. (RCHA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is RICH PHARMACEUTICALS, INC.'s lead drug candidate?

RICH PHARMACEUTICALS, INC.'s most advanced tracked candidate is rp-323 (Preclinical) for Stroke.

Get the full picture on RICH PHARMACEUTICALS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar